We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App

Russia’s Sputnik V COVID-19 Vaccine Begins Global Phase 3 Trials

By HospiMedica International staff writers
Posted on 19 Aug 2020
Print article
Russia’s Sputnik V, the world’s first registered vaccine against COVID-19, has begun Phase III clinical trials.

Similar to the approach adopted for the AstraZeneca-Oxford COVID-19 vaccine, the Sputnik-V vaccine also uses the common cold-causing adenovirus that has been modified to carry genes for the “spike” protein that coats the coronavirus, in order to prime the body to recognize if a real COVID-19 infection strikes. The vaccine, developed jointly by the Gamaleya Research Institute and the Russian Defense Ministry, requires an initial injection and a booster shot 21 days later to confer one- to two-year immunity.

According to details provided on a new website launched by the Russia Direct Investment Fund (RDIF) to share the details of the vaccine with the public and scientists around the world, Sputnik V has gone through all stages of pre-clinical trials with experiments on different types of animals, including two types of primates. The Phase 1 and 2 clinical trials of the vaccine were completed on August 1, 2020. All the volunteers were feeling well, and no unforeseen or unwanted side effects were observed. The vaccine induced strong antibody and cellular immune responses and not a single participant of the current clinical trials was infected with COVID-19 after being administered the vaccine.

The Sputnik V website states that the vaccine’s efficacy was confirmed by high precision tests for antibodies in the blood serum of volunteers (including an analysis for antibodies that neutralize the coronavirus), as well as the ability of the immune cells of the volunteers to activate in response to the spike S protein of the coronavirus, which indicates the formation of both antibody and cellular immune vaccine response. Sputnik V’s Phase 3 clinical trial involving more than 2,000 people has now begun in Russia, and a number of Middle Eastern (UAE and Saudi Arabia), and Latin American countries (Brazil and Mexico).

Gold Supplier
Disposable Protective Suit For Medical Use
Disposable Protective Suit For Medical Use
Emergency Trolley
Emergency Trolley – 74403
Multi-Parameter Patient Monitor
CT Injector Syringe
MDT CT Injector Syringe

Print article
FIME - Informa



view channel
Image: The AI tool can also tackle dangerous inequalities in heart attack diagnosis (Photo courtesy of Freepik)

AI Algorithm Integrates Cardiac Troponin Test Results with Clinical Data to Quickly Rule out Heart Attacks in Patients

The accepted standard for diagnosing myocardial infarction, or heart attack, involves assessing the blood for troponin levels. However, this approach applies the same benchmark for all patients, failing... Read more

Critical Care

view channel
Image: New technology gives patients the power to heal chronic wounds using their own blood (Photo courtesy of RedDress)

POC Solution Creates In Vitro Blood Clots from Patient’s Own Whole Blood in Real-Time to Treat Post-Surgical Wounds

Blood clots are a natural mechanism of the body's healing process. However, for chronic wounds resulting from diabetes and other conditions, blood is unable to reach these areas, hampering the initiation... Read more

Surgical Techniques

view channel
Image: The deployable electrodes are ideal for minimally invasive craniosurgery (Photo courtesy of EPFL)

Soft Robotic Electrode Offers Minimally Invasive Solution for Craniosurgery

Minimally invasive medical procedures offer numerous benefits to patients, including decreased tissue damage and shorter recovery periods. However, creating equipment that can pass through a small opening... Read more

Health IT

view channel
Image: First ever institution-specific model provides significant performance advantage over current population-derived models (Photo courtesy of Mount Sinai)

Machine Learning Model Improves Mortality Risk Prediction for Cardiac Surgery Patients

Machine learning algorithms have been deployed to create predictive models in various medical fields, with some demonstrating improved outcomes compared to their standard-of-care counterparts.... Read more

Point of Care

view channel
Image: IntelliSep is the first FDA-cleared diagnostic tool to assess cellular host response to aid in identifying ED patients with sepsis (Photo courtesy of Cytovale)

Rapid Microfluidic Test Demonstrates Efficacy as Diagnostic Aid to Improve Sepsis Triage in ED

Sepsis is the primary cause of mortality worldwide, accounting for over 350,000 fatalities annually in the United States alone, a figure that surpasses deaths from opioid overdoses, prostate cancer, and... Read more
Copyright © 2000-2023 Globetech Media. All rights reserved.